|
| R+DA-EPOCH方案治疗弥漫大B细胞淋巴瘤的疗效 |
| Therapeutic effect of Rituximab combined with DA-EPOCH on DLBCL |
| 投稿时间：2019-09-16 |
| DOI：10.3969/j.issn.1000-0399.2020.07.003 |
| 中文关键词: 利妥昔单抗 弥漫大B细胞淋巴瘤 DA-EPOCH方案 疗效 |
| 英文关键词: Rituximab Diffused large B cell lymphoma DA-EPOCHregimen Therapeutic effect |
| 基金项目:安徽省2018年度重点研究与开发计划项目（项目编号：1804h08020249） |
|
| 摘要点击次数: 1501 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 探讨R+DA-EPOCH方案治疗弥漫大B细胞淋巴瘤（DLBCL）的临床疗效和安全性。方法 选择2015年5月至2018年1月中国科学技术大学附属第一医院西区（安徽省肿瘤医院）收治的30例初治DLBCL患者，采用R+DA-EPOCH方案治疗，评价临床疗效与安全性。结果 30例患者中，完全缓解（CR）14例（46.67%），部分缓解（PR）7例（23.33%）。双重表达淋巴瘤患者治疗有效率为92.31%，非双重表达淋巴瘤患者治疗有效率为52.94%，差异具有统计学意义（P<0.05）。24个月的无进展生存期（PFS）率为86.54%，至随访终点的PFS率为78.67%。结论 R+DA-EPOCH方案对于DLBCL的有效率较高，尤其可克服双重表达对疾病预后的影响，不良反应可耐受，安全性高，值得临床推广应用。 |
| 英文摘要: |
| Objective To observe the clinical efficacy and safety of R+DA-EPOCH regimen in the treatment of diffuse large B-cell lymphoma(DLBCL).Methods Thirty patients with DLBCL admitted from May 2015 to January 2018 were treated with R+DA-EPOCH. The clinical efficacy and safety were evaluated. Results Among all patients,14 patients (46.67%) had complete response (CR) and 7 patients (23.33%) had partial response (PR). The response rate was 92.31% in DPL patients and 52.94% in non DPL patients,and the difference was statistically significant(P<0.05).The 24 months’ PFS rate was 86.54%, and the PFS rate was 78.67% at the endpoint.Conclusions It is worth while to popularize the R+DA-EPOCH regimen for its high overall response rate in DLBCL, especially its capacity overcome the double expression on prognosis, as well as its high tolerance and safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
